All Reports

Reports / Nephrology Reports / Market Dynamix: Multi-Specialty Management of Anemia US

Market Dynamix: Multi-Specialty Management of Anemia US

Anemia is a condition that develops when the blood does not contain hemoglobin. The most common type is related to iron-deficiency, but there are multiple other causes such as chronic diseases (like chronic kidney disease), cancer and chemotherapy treatments, autoimmune conditions, and bleeding disorders.
Spherix has extensive coverage of renal anemia from the perspective of nephrologists. The purpose of this study is to understand how other specialists—namely hematologists, oncologists, gastroenterologists, cardiologists, and endocrinologists—diagnose and treat anemia and also to get an understanding about the types of anemia they see and how they co-manage patients with other physicians. Emphasis is on the use of iron therapies, ESAs, blood transfusions and reaction to the product profile of a novel class of oral anemia agents known as the HIF-PH inhibitors, currently in development for renal anemia and MDS.

Market Dynamix™: Multi-Specialty Management of Anemia US study combines qualitative feedback from leading opinion leaders with large scale quantitative feedback of “in the trenches” physicians. Additional interviews with both payers and dialysis chain financial analysts are conducted to elucidate how the current treatment patterns may potentially morph.

Market Dynamix™: Multi-Specialty Management of Anemia (US) combines the results of a large, quantitative survey of 316 PCPs and target specialists with qualitative feedback from a subset of the survey respondents for additional color (n=25, 5 per specialty).

Learn more about Market Dynamix™ reports here.

  • How common is anemia in the practices of PCPs, hematology/oncology specialists, cardiologists, endocrinologists, and gastroenterologists? What are the underlying causes and how do they differ by specialty? How common is iron deficiency?
  • How do the various specialists define anemia? What tests do they use to diagnose anemia?
  • How often do the different specialists treat anemia vs. refer out to another specialist? When they do treat, which anemia agents do they prescribe and how satisfied are they with these treatments?
  • What are the barriers to (increased) use of ESAs and IV iron? How familiar are specialists with the various ESA and iron brands, including Akebia’s Auryxia? How willing are they to prescribe these agents?
  • How aligned are the specialists when it comes to disease awareness and anemia management opinions?
  • What attributes would be most desired in a new anemia treatment? What unmet needs would be filled?
  •  Are specialists aware of any anemia treatments in development? How familiar are these physicians with the HIF-PH inhibitors? How willing would practitioners be to initiate therapy with a HIF-PHI with-out nephrology guidance for patients with CKD anemia?

Oral iron—ferrous sulfate, polysaccharide iron complex, Auryxia
IV Iron—INFeD/Dexferrum, Venofer, Ferrlecit, Injectafer, Feraheme
ESAs—Epogen, Procrit, Retacrit, Aranesp

Download Report Overview (PDF)

RELATED CONTENT

Janssen’s INVOKANA (canagliflozin) Gets Boost Over Competitors with FDA Approval for Diabetic Kidney Disease and a Newly Minted Collaboration with Renal Giant, Vifor Pharma – November 25, 2019
>VIEW ARTICLE

REQUEST REPORT